FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380478> ?p ?o ?g. }

• W4387380478 abstract "Abstract Background: The application of immune checkpoint inhibitors (ICIs) has changed the treatment of advanced hepatocellular carcinoma. Transcatheter arterial chemoembolization (TACE) is a first-line treatment for intermediate hepatocellular carcinoma. serving as a local inducer of immunogenic cell death, the efficacy and safety of combined use with ICI have not been evaluated. Although there have been prospective studies aimed at evaluating the efficacy and safety of ICI combined with TACE in BCLC stage B HCC patients, there are few reports on the evaluation of BCLC stage C patients with distant metastasis or portal vein cancer thrombus. Method: Data of unresectable hepatocellular carcinoma patients received PD-1 inhibitor and TACE were collected in Xijing Hospital from June 2019 to December 2022. The tumor response was evaluated according to the Solid Tumor Modified Response Evaluation Standard (mRECIST), including complete response (CR), partial response (PR), disease stability (SD), disease progression (PD)，objective response rate (ORR) ,and disease control rate (DCR).The progression-free survival (PFS) and overall survival (OS) were used to estimate therapy efficacy. The treatment-related adverse events were evaluated based on National Cancer Institute Common Adverse Event Evaluation Criteria (CTCAE) version 5.0. Result: A total of 42 patients with unresectable hepatocellular carcinoma were included in this study, including 34 males (80.5%) and 8 females (19.5%); The average age is 55 years, ranging from (34 - 72); The median follow-up time was 12.3 months, with an ORR of 42.9% and a DCR of 90.5% as of the follow-up time; The median PFS is 7.5 months (95% CI: 5.76-9.23), and the median OS has not yet been reached; 6-months PFS was 62.2%. Safety analysis showed that 41 (97.6%) patients experienced treatment-related adverse reactions, mainly including elevated AST and ALT, fever, elevated bilirubin, hypothyroidism, nausea, abdominal pain, and rash. 40 patients had grade 1/2 adverse reactions, and only 1 patient had grade 3 adverse reactions, manifested as intolerable rash, nausea, and vomiting. Treatment was terminated due to symptomatic treatment and discontinuation of medication. In this study, 3patients with unresectable hepatocellular carcinoma were treated with PD-1 inhibitor combined with TACE to achieve good tumor reduction effect, and underwent liver cancer resection surgery. Conclusion: For patients with unresectable hepatocellular carcinoma, whether in BCLC stage B or stage C, effective systemic therapy (PD-1 inhibitor) combined with local therapy (TACE) can achieve a high rate of tumor regression and objective response. Some patients may even pursue surgical treatment opportunities, and the treatment related adverse reactions are controllable, which is expected to provide new options for extending survival of unresectable hepatocellular carcinoma patients." @default.
• W4387380478 created "2023-10-06" @default.
• W4387380478 creator A5002287326 @default.
• W4387380478 creator A5025808458 @default.
• W4387380478 creator A5025849812 @default.
• W4387380478 creator A5068978771 @default.
• W4387380478 creator A5077969420 @default.
• W4387380478 date "2023-10-05" @default.
• W4387380478 modified "2023-10-14" @default.
• W4387380478 title "The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma" @default.
• W4387380478 cites W1996703005 @default.
• W4387380478 cites W2059377623 @default.
• W4387380478 cites W2194546364 @default.
• W4387380478 cites W2289095651 @default.
• W4387380478 cites W2582878252 @default.
• W4387380478 cites W2606367731 @default.
• W4387380478 cites W2888049100 @default.
• W4387380478 cites W2888394278 @default.
• W4387380478 cites W2911646196 @default.
• W4387380478 cites W2912201468 @default.
• W4387380478 cites W2980064491 @default.
• W4387380478 cites W2984538501 @default.
• W4387380478 cites W2990602950 @default.
• W4387380478 cites W3004910654 @default.
• W4387380478 cites W3036902489 @default.
• W4387380478 cites W3149853307 @default.
• W4387380478 cites W4220732956 @default.
• W4387380478 cites W4221099098 @default.
• W4387380478 cites W4282966628 @default.
• W4387380478 cites W4289522150 @default.
• W4387380478 cites W4366984575 @default.
• W4387380478 doi "https://doi.org/10.21203/rs.3.rs-3369412/v1" @default.
• W4387380478 hasPublicationYear "2023" @default.
• W4387380478 type Work @default.
• W4387380478 citedByCount "0" @default.
• W4387380478 crossrefType "posted-content" @default.
• W4387380478 hasAuthorship W4387380478A5002287326 @default.
• W4387380478 hasAuthorship W4387380478A5025808458 @default.
• W4387380478 hasAuthorship W4387380478A5025849812 @default.
• W4387380478 hasAuthorship W4387380478A5068978771 @default.
• W4387380478 hasAuthorship W4387380478A5077969420 @default.
• W4387380478 hasBestOaLocation W43873804781 @default.
• W4387380478 hasConcept C121608353 @default.
• W4387380478 hasConcept C126322002 @default.
• W4387380478 hasConcept C141071460 @default.
• W4387380478 hasConcept C143998085 @default.
• W4387380478 hasConcept C146357865 @default.
• W4387380478 hasConcept C151730666 @default.
• W4387380478 hasConcept C197934379 @default.
• W4387380478 hasConcept C2776231280 @default.
• W4387380478 hasConcept C2776694085 @default.
• W4387380478 hasConcept C2777546739 @default.
• W4387380478 hasConcept C2778019345 @default.
• W4387380478 hasConcept C2778822529 @default.
• W4387380478 hasConcept C2779984678 @default.
• W4387380478 hasConcept C71924100 @default.
• W4387380478 hasConcept C86803240 @default.
• W4387380478 hasConcept C90924648 @default.
• W4387380478 hasConceptScore W4387380478C121608353 @default.
• W4387380478 hasConceptScore W4387380478C126322002 @default.
• W4387380478 hasConceptScore W4387380478C141071460 @default.
• W4387380478 hasConceptScore W4387380478C143998085 @default.
• W4387380478 hasConceptScore W4387380478C146357865 @default.
• W4387380478 hasConceptScore W4387380478C151730666 @default.
• W4387380478 hasConceptScore W4387380478C197934379 @default.
• W4387380478 hasConceptScore W4387380478C2776231280 @default.
• W4387380478 hasConceptScore W4387380478C2776694085 @default.
• W4387380478 hasConceptScore W4387380478C2777546739 @default.
• W4387380478 hasConceptScore W4387380478C2778019345 @default.
• W4387380478 hasConceptScore W4387380478C2778822529 @default.
• W4387380478 hasConceptScore W4387380478C2779984678 @default.
• W4387380478 hasConceptScore W4387380478C71924100 @default.
• W4387380478 hasConceptScore W4387380478C86803240 @default.
• W4387380478 hasConceptScore W4387380478C90924648 @default.
• W4387380478 hasLocation W43873804781 @default.
• W4387380478 hasOpenAccess W4387380478 @default.
• W4387380478 hasPrimaryLocation W43873804781 @default.
• W4387380478 hasRelatedWork W1584669207 @default.
• W4387380478 hasRelatedWork W2024340610 @default.
• W4387380478 hasRelatedWork W2024938637 @default.
• W4387380478 hasRelatedWork W2899528185 @default.
• W4387380478 hasRelatedWork W2899585536 @default.
• W4387380478 hasRelatedWork W3030034569 @default.
• W4387380478 hasRelatedWork W3031735911 @default.
• W4387380478 hasRelatedWork W3091350106 @default.
• W4387380478 hasRelatedWork W3172671185 @default.
• W4387380478 hasRelatedWork W4207052486 @default.
• W4387380478 isParatext "false" @default.
• W4387380478 isRetracted "false" @default.
• W4387380478 workType "article" @default.